JP2023156372A5 - - Google Patents

Download PDF

Info

Publication number
JP2023156372A5
JP2023156372A5 JP2023123302A JP2023123302A JP2023156372A5 JP 2023156372 A5 JP2023156372 A5 JP 2023156372A5 JP 2023123302 A JP2023123302 A JP 2023123302A JP 2023123302 A JP2023123302 A JP 2023123302A JP 2023156372 A5 JP2023156372 A5 JP 2023156372A5
Authority
JP
Japan
Prior art keywords
cancer
compound
medicament
manufacture
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2023123302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023156372A (ja
JP7778750B2 (ja
Filing date
Publication date
Priority claimed from PCT/US2018/046203 external-priority patent/WO2019032958A1/en
Application filed filed Critical
Publication of JP2023156372A publication Critical patent/JP2023156372A/ja
Publication of JP2023156372A5 publication Critical patent/JP2023156372A5/ja
Priority to JP2025168516A priority Critical patent/JP2026012715A/ja
Application granted granted Critical
Publication of JP7778750B2 publication Critical patent/JP7778750B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2023123302A 2017-08-11 2023-07-28 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態 Active JP7778750B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025168516A JP2026012715A (ja) 2017-08-11 2025-10-06 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11
US62/544,277 2017-08-11
PCT/US2018/046203 WO2019032958A1 (en) 2017-08-11 2018-08-10 SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE
JP2020530441A JP7424639B2 (ja) 2017-08-11 2018-08-10 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2020530441A Division JP7424639B2 (ja) 2017-08-11 2018-08-10 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025168516A Division JP2026012715A (ja) 2017-08-11 2025-10-06 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Publications (3)

Publication Number Publication Date
JP2023156372A JP2023156372A (ja) 2023-10-24
JP2023156372A5 true JP2023156372A5 (cg-RX-API-DMAC7.html) 2024-04-12
JP7778750B2 JP7778750B2 (ja) 2025-12-02

Family

ID=63405430

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020530441A Active JP7424639B2 (ja) 2017-08-11 2018-08-10 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
JP2023123302A Active JP7778750B2 (ja) 2017-08-11 2023-07-28 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態
JP2025168516A Pending JP2026012715A (ja) 2017-08-11 2025-10-06 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020530441A Active JP7424639B2 (ja) 2017-08-11 2018-08-10 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025168516A Pending JP2026012715A (ja) 2017-08-11 2025-10-06 3-(5-フルオロベンゾフラン-3-イル)-4-(5-メチル-5H-[1,3]ジオキソロ[4,5-f]インドール-7-イル)ピロール-2,5-ジオンの固体形態

Country Status (16)

Country Link
US (3) US11136334B2 (cg-RX-API-DMAC7.html)
EP (1) EP3665176B1 (cg-RX-API-DMAC7.html)
JP (3) JP7424639B2 (cg-RX-API-DMAC7.html)
KR (3) KR20250070131A (cg-RX-API-DMAC7.html)
CN (2) CN117362305A (cg-RX-API-DMAC7.html)
AU (3) AU2018313259B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020002892A2 (cg-RX-API-DMAC7.html)
CA (1) CA3072240A1 (cg-RX-API-DMAC7.html)
DK (1) DK3665176T3 (cg-RX-API-DMAC7.html)
ES (1) ES2974328T3 (cg-RX-API-DMAC7.html)
FI (1) FI3665176T3 (cg-RX-API-DMAC7.html)
IL (2) IL272556B2 (cg-RX-API-DMAC7.html)
MX (3) MX2020001547A (cg-RX-API-DMAC7.html)
PL (1) PL3665176T3 (cg-RX-API-DMAC7.html)
PT (1) PT3665176T (cg-RX-API-DMAC7.html)
WO (1) WO2019032958A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11407759B2 (en) * 2017-10-16 2022-08-09 Actuate Therapeutics Inc. Solid forms of 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxolo[4,5-f]indol-7-yl)pyrrole-2,5-dione
KR20210038429A (ko) * 2018-05-17 2021-04-07 액투에이트 테라퓨틱스 인크. 글리코겐 신타제 키나제 3 형태 베타 억제제를 사용한 특발성 폐 섬유증의 치료
CA3251821A1 (en) * 2022-06-27 2024-01-04 Actuate Therapeutics, Inc. ORAL DOSAGE FORMS OF ELRAGLUSIB

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2673368C (en) 2006-12-19 2014-10-28 The Board Of Trustees Of The University Of Illinois 3-benzofuranyl-4-indolyl maleimides as potent gsk3 inhibitors for neurogenerative disorders
JP2013515737A (ja) 2009-12-23 2013-05-09 アークル インコーポレイテッド 精製されたピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにその調製方法および使用方法

Similar Documents

Publication Publication Date Title
TWI455723B (zh) 納曲酮及安非他酮於治療超重或肥胖病患之用途
JP2024540183A5 (cg-RX-API-DMAC7.html)
JP2020508339A5 (cg-RX-API-DMAC7.html)
JP2011522816A5 (cg-RX-API-DMAC7.html)
RederPh. D et al. Desflurane versus propofol maintenance for outpatient laparoscopic cholecystectomy
JP2023175694A5 (cg-RX-API-DMAC7.html)
JP2025020117A5 (cg-RX-API-DMAC7.html)
JP2010540555A5 (cg-RX-API-DMAC7.html)
JP2024516795A5 (cg-RX-API-DMAC7.html)
RU2008141076A (ru) Применение терапевтического человеческого альбумина для изготовления лекарственного средства для лечения пациентов, страдающих когнитивными расстройствами
EA200800663A1 (ru) Способ и средство профилактики и лечения нарушенного дыхания во время сна
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
JP2023531675A5 (cg-RX-API-DMAC7.html)
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
JP2022523530A5 (cg-RX-API-DMAC7.html)
MX2024007642A (es) Uso de tabletas de desintegracion oral de riluzol para tratar enfermedades.
JP2005508963A5 (cg-RX-API-DMAC7.html)
JP2005502579A5 (cg-RX-API-DMAC7.html)
JP2013536837A5 (cg-RX-API-DMAC7.html)
JP2024001040A5 (cg-RX-API-DMAC7.html)
JP2002544227A5 (cg-RX-API-DMAC7.html)
MX2026002937A (es) Nuevas fenilalquilaminas y su uso en el tratamiento de trastornos psiquiatricos
RU2006143659A (ru) Применение ребоксетина для лечения боли
JP2023531930A5 (cg-RX-API-DMAC7.html)
JP2024543111A5 (cg-RX-API-DMAC7.html)